New Treatment Shows Promise Against Antibiotic-Resistant Helicobacter pylori & Stomach Cancer Risk

Researchers at the Technical University of Munich have developed new chemical variants of the antibiotic metronidazole that demonstrate up to 60 times greater effectiveness against Helicobacter pylori, a bacterium responsible for a significant number of stomach cancer cases worldwide. The findings, published in the journal Nature Microbiology, offer a potential breakthrough in treating infections increasingly resistant to existing therapies.

Approximately 43 percent of the global population harbors Helicobacter pylori, which can cause inflammation of the stomach lining, ulcers, and is a major risk factor for gastric cancer. In Germany alone, around 16,000 people are diagnosed with stomach cancer annually, with a substantial proportion linked to this bacterial infection, according to the source material.

Current treatment typically involves a combination of antibiotics, including metronidazole, but rising bacterial resistance is diminishing the efficacy of these regimens. The research team, led by Michaela Fiedler and Marianne Pandler, focused on modifying the molecular structure of metronidazole to enhance its binding affinity to target proteins within the bacterium. “Based on our new fundamental findings, we developed chemically slightly modified variants of metronidazole, so-called ether derivatives. This molecular optimization leads to the fact that the active ingredient can attach to the target proteins better and more stably,” Fiedler and Pandler stated.

The study revealed that metronidazole’s effectiveness stems from its ability to induce oxidative stress within the bacterial cell, damaging essential components. But, the precise mechanisms were previously unclear. Researchers discovered that the antibiotic disrupts two key protective mechanisms within H. Pylori: a protein responsible for repairing damaged proteins and another that neutralizes harmful oxygen compounds. The newly developed ether derivatives exhibited significantly improved potency against the bacterium, even against resistant strains.

Importantly, laboratory tests indicated that the new compounds were not more toxic to human cells. In experiments conducted on mice, the modified metronidazole successfully eradicated the infection at considerably lower doses than those used in standard treatments. The research suggests a potential benefit for the gut microbiome, as the new compounds appeared to cause less disruption to beneficial bacteria compared to conventional antibiotics.

The World Health Organization has identified Helicobacter pylori as a high-priority pathogen for research and development of new antibiotics due to increasing resistance to existing medications. According to the German Center for Infection Research (DZIF), over four billion people worldwide are infected with H. Pylori, leading to over 800,000 cases of stomach cancer each year.

While the results are promising, the researchers emphasize that these are preclinical findings. Clinical trials are now necessary to determine the safety and efficacy of the new compounds in humans.